Cargando…
Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer
INTRODUCTION: Aromatase enzyme activity is predominant in adipose tissue. This has led to speculation that aromatase activity is elevated in obese women and subsequently decreased the clinical activity of adjuvant aromatase inhibitors (AIs) in women with estrogen receptor positive (ER+) breast cance...
Autores principales: | Zekri, Jamal, Farag, Kamel, Allithy, Ahmed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880223/ https://www.ncbi.nlm.nih.gov/pubmed/29662534 http://dx.doi.org/10.3332/ecancer.2018.821 |
Ejemplares similares
-
Assessment of bone health in breast cancer patients starting adjuvant aromatase inhibitors: A quality improvement clinical audit
por: Zekri, Jamal, et al.
Publicado: (2016) -
Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer
por: Zekri, Jamal, et al.
Publicado: (2023) -
Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment
por: Jung, Yongsik, et al.
Publicado: (2018) -
An examination of obesity and breast cancer survival in post-menopausal women.
por: Katoh, A., et al.
Publicado: (1994) -
Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study
por: El-attar, Aya Ahmed, et al.
Publicado: (2022)